AbbVie Reports Estimate-Beating Fourth-Quarter Earnings Results
AbbVie (NYSE: ABBV) recently delivered an encouraging earnings report for the last three months of 2019. Revenue that grew 2% year over year to $8.7 billion surpassed consensus estimates by $20 million. On the bottom line, adjusted earnings grew 13% to $2.21 per share which was $0.02 more than the average Wall Street analyst had predicted.
International sales of Humira fell 27% year over year as a result of biosimilar competition for the extremely successful rheumatoid arthritis injection. In the U.S., where biosimilar versions have been approved by the Food and Drug Administration but still remain unaccessible, Humira sales grew 10% year over year.
Image source: Getty Images.
Source Fool.com
